Happy 2012 to all our friends of the Department of Urology at Thomas Jefferson University! We have a lot of news to report from the last year so we have decided to produce two editions of the Jefferson Urology News Year in Review. The first part will cover important events including the Departmental Seminar on Billing and Coding presented by Dr. Mike Ferragamo and Dr. Bill Steers’ visit as our 2011 D.M. Davis Visiting Professor among other notable visitors. Follow-up newsletters will also highlight our Prostate Cancer related activities including our Philadelphia Eagles Prostate Cancer Awareness Campaign.

CASTLE CONNOLLY RECOGNIZES UROLOGY PHYSICIANS AS AMERICA’S TOP DOCTORS

Castle Connolly Top Doctors listed four of our physicians as Top Doctors in Philadelphia Magazine and nationally in America’s Top Doctors rating. They included Drs. Demetrius Bagley, Leonard Gomella, Patrick Shenot and Edouard Trabulsi.

Special congratulations to Dr. Gomella, on being selected as one of America’s Top Doctors for Cancer for 5 years! Only a small percentage of physicians have earned the prestigious recognition of being an America’s Top Doctor for Cancer at all. As noted in the announcement by Castle Connolly “Many, many fewer have earned it five years in a row.” Each year the 5 Yr Award has been a result of Castle Connolly’s rigorous peer nominated, expert reviewed selection process. This year Castle Connolly and American Registry worked together to launch milestone anniversary plaques for the physicians most consistently honored as Top Doctors.

Congratulations to Dr. Ed Trabulsi who was nominated as “America’s Top Doctors for Cancer” by Castle-Connolly in 2011.
MICHAEL A. FERRAGAMO M.D., FACS CONDUCTS SPECIAL SEMINAR SERIES: “Coping with Coding in the Urological Practice”.

Dr. Michael A. Ferragamo visited our Department and gave multiple sessions on “Coping with Coding in the Urological Practice”. Each session was unique to the audience such as Physicians, Residents, Physician Assistants and Nurse Practitioners, whereas upgrades and billing issues were addressed to the administrators and billing staff.

Dr. Ferragamo received his undergraduate degree from Columbia University in New York City, his medical degree from State University of New York, Downstate Medical Center, Brooklyn, New York, and completed his urological training at the Kings County Hospital and Medical Center, Brooklyn, NY. Dr. Ferragamo is an Assistant Clinical Professor of Urology at the State University of New York, University Hospital and School of Medicine at Stony Brook, Long Island, NY. He is also the Senior Urologist with Urocare Associates of New York, a private urological practice for which he oversees coding and reimbursement issues. Dr. Ferragamo is a consultant for the Physicians Reimbursement Systems, Denver, Colorado, the American Association of Professional Coders as well as a coding consultant for a number of private practices, medical institutions, clinics, and hospitals including The Lahey Clinic, Burlington, Mass., The Mayo Clinic, and many others. Dr. Ferragamo has given numerous seminars and national teleconferences on urological coding and reimbursement. He has published papers on urology coding and reimbursement in the Journal of Endourology and Contemporary Urology and is consulting Editor for “Urology Coding Alert”, a monthly newsletter devoted to proper urology coding and reimbursements.

ADAM KOPPEL, MD, PhD, MBA VISITING LECTURER

Dr. Adam Koppel gave an informative presentation at our Grand Rounds (5/12/11) entitled “Novel Drug Therapies in Hormonal Resistant Prostate Cancer (HRPC) from an Investor’s Perspective: Controversies in Clinical Trials and Market Adoption”.

Dr. Koppel received his M.D. and Ph.D. from the University of the Pennsylvania School of Medicine, his MBA from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar and his BA from Harvard University. Dr. Adam Koppel is presently a Public Equity Investor in the Healthcare Division at Bain Capital and is Managing Director of the Brookside Fund. Most importantly he is the son of his proud father, Dr. Max Koppel, Clinical Associate Professor of Urology.
The “Urology Symposium in Avalon, NJ” was held on Saturday, September 10, 2011. This has become an annual educational event over the last 11 years providing our Jefferson urology residents and staff with subjects presented by the faculty in a less formal atmosphere. Dr. Demetrius Bagley co-chaired the event with Dr. Kelly Healy, C.R. Bard Fellow in Endourology & Laparoscopy at Jefferson.

The meeting featured three guest speakers this year: Dr. Michael Grasso, III, Professor of Urology, Medical College of New York, Valhalla, NY (TJUH Urology Residency 1989-1992), Dr. Michael Erhard, Chief of Pediatric Urology, Nemours Foundation, Jacksonville, FL (TJUH Urology Residency 1991-1995), and Dr. Timothy Showalter, an Assistant Professor and the Associate Director of the Residency Program in the Department of Radiation Oncology at Jefferson.

During the meeting Dr. Kelly Healy served as the Program Chair and introduced the following faculty and their presentations:

Leonard Gomella, M.D. - “Blue Light Cystoscopy in the Management of Bladder Cancer”
Michael Erhard, M.D. – “Reconstructive Techniques in Hypospadias”
Scott Hubosky, M.D. – “Update on Management of Upper Tract Urothelial Carcinoma in Hereditary Non-Polyposis Colon Cancer (HNPC) Patients”
Kelly A. Healy, M.D. – “Ureteroscopy: A Historical Perspective”
Michael Grasso, M.D. – “Endourology Update: Advances and Innovations”
David McGinnis, M.D. – “Robotic Prostatectomy: Complications and Management”
Timothy Showalter, M.D. – “Reconsidering Adjuvant Radiation Therapy for High-Risk Prostate Cancer: What are the Issues?”
Nir Kleinmann, M.D. – “Tumor suppressive effects of adiponectin in renal cell carcinoma (RCC): in vitro studies”

In addition to our Urology Faculty, local urologists, former residents, nursing and OR staff also attended the event. Jefferson Urology is a long time supporter of the interdisciplinary approach to medical education and Dr. Bagley has been a local leader in this approach. The Symposium was most informative and all look forward to future gatherings among our colleagues in Avalon. A tremendous hand to Dr. Kelly Healy on this industrious endeavor!
The Department of Urology had the distinct pleasure of hosting Dr. William D. Steers as the “David M. Davis Visiting Professor 2011.” Dr. Steers is the “Paul Mellon” Professor of Urology and the Chairman of the Department of Urology at the University of Virginia. Dr. Steers graduated from Cornell University with degree in chemical engineering and received his medical degree from the Medical College of Ohio. He completed his residency at the University of Texas and M.D. Anderson Hospital, followed by a fellowship in Neurobiology and Pharmacology at the University of Pittsburgh. Dr. Steers has been a faculty member at the University of Virginia since 1988 and became Chair of the Department of Urology in 1995.

Dr. Steers’ diverse clinical interests span urinary incontinence, BPH, neurogenic bladder and robotic surgery for prostate cancer. He is known as an expert in the complications of prostate cancer treatments (incontinence and impotence). Dr. Steers is a member of the FDA’s Reproductive Medicine Advisory Panel and chaired the NIH’s Urinary Incontinence and Interstitial Cystitis Clinical Trials groups. He has been Principal Investigator on numerous NIH grants including NIDDK’s O’Brien Research Center. His team has been pivotal in numerous clinical trials for incontinence and erectile dysfunction. Dr. Steers was a principal investigator on the original clinical trials on the use of viagra™ for erectile dysfunction.

During Dr. Steers’ visit, he presented the following lectures: “The Age of Molecular Surgery” and the “Neural Basis for LUTS Due To BPH”. These lectures were informative and well received by the diverse audience of urologists, residents, students and nurses. Our urology residents had the opportunity to discuss several complex neuro-urology cases, with Dr. Steers. Thanks to Drs. Johannes and Patel, the urology chief residents, who coordinated the itinerary and the residents for well-prepared and organized case presentations. Dr. Steers enjoyed the day, appreciated the hospitality and getting to learn more about our department.

Congratulations to Dr. Adeep Thumar who received the 2011 Max Koppel, M.D., MPH, MBA Award for the highest score on the in-service examination. Dr. Thumar has captured this award for the past two years.
The Department of Urology bid farewell to their Chief Residents - Dr. Jim Johannes and Dr. Jitesh Patel. The Residents’ Graduation was held immediately after the David M. Davis Visiting Professorship. The D. M. Davis Graduation banquet was hosted by Drs. Leonard and Tricia Gomella onboard one of the most notable battleships in the US Navy's history, the Battleship New Jersey. The Battleship New Jersey is an 887-foot long, 45,000-ton living window on the most important half-century in U.S. history and all guests were offered tours.

Drs. Gomella initiated the event and startled the guests with a salute to the Chiefs by the firing of the ship’s gun across the Delaware in the direction of TJU, our home base. The dinner was held outside in the forward section of the ship, called the Forecastle. On the forecastle we had panoramic views of the Delaware River, New Jersey State Aquarium, Benjamin Franklin Bridge, and the Philadelphia skyline with the ship’s superstructure and two forward 16-inch gun turrets in the background. This very unique venue will be remembered by all especially the residents and visiting professor who received model replicas of the Battleship New Jersey.

Our graduating chief residents were the 3rd Class of residents selected since Dr. Gomella’s leadership as chairman. The Gomellas have continued their tradition with gifts of their own personal “Bobble Head Doll” that were exact matches!

Dr. Johannes joined the Lehigh Valley Medical Group, Allentown, PA and Dr. Patel began a solo private practice in urology at Emory Eastside Medical Center, Atlanta, GA. These chief residents will surely be missed by the department. The faculty, residents and staff wish them happiness and success in both their personal and professional lives.
Dr. Costas Lallas, Associate Professor of Urology and TJUH Director of Robotics was recently featured in a spotlight article in the Summer 2011 Issue of Jefferson Alumni Magazine. The article is titled “Scalpel, Forceps, Joystick: Surgeons Turn To Robots for Minimally Invasive Procedures.”
2011 RESIDENCY MATCH RESULTS

The Department of Urology is proud to announce the Urology Residents for 2011 at Thomas Jefferson University Hospital as Drs. Patricia Lewandoski, Amar Ravel and Kymora Scotland. These three new urology residents started as interns in the Department of Surgery on July 1, 2011.

Patricia Lewandoski, M.D. is a graduate of the University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ. Her undergraduate degrees in Biology and Religion are from Rutgers, The State University of New Jersey, New Brunswick, NJ.

Amar Ravel, M.D. received his Medical Doctorate Degree from Florida State University College of Medicine and his BS in Biomedical Sciences from University of South Florida, Tampa, FL.

Kymora Scotland, M.D., Ph.D. received her medical degree from Weill Cornell Medical College and Doctorate of Philosophy in Developmental Biology and Pharmacology from Weill Cornell Graduate School of Medical Sciences, NY, NY. Her doctoral thesis focused on the “Regulation of Stem Cell Pluripotency and Differentiation”. Kymora’s undergraduate studies were in Chemistry with BA from Hunter College, NY, NY.

For the 2010-2011 Academic Year, our program received 230 electronic submissions. Fifty-three applicants were granted interviews and the department ranked 30. Nationally, only 271 urology positions were available this year, making urology programs one of the more competitive specialties. Three hundred and six individuals were ranked by programs with 268 applicants matched and 71 not matched. The Department of Urology is grateful for the orchestrations of this successful program to Dr. Patrick Shenot, Residency Program Director and the support of Dr. Dolores Byrne and Nicole Eppright, our new Residency Coordinator.

The Department of Urology is pleased to congratulate the following 4th-year Jefferson Medical College students, who matched at the following programs:

Paul Chung, M.D. - University of Texas South Western Medical School, Dallas TX
Matthew Ferroni, M.D. - University of Pittsburgh Medical Center, School of Medicine and Public Health, Pittsburgh, PA
Jennifer Heckman, M.D. - University of Wisconsin, School of Medicine, Madison WI

JEFFERSON MEDICAL COLLEGE
NATIONAL RECOGNITION OF HIGHEST UROLOGY RESIDENCY MATCHES

The Journal of Urology recently listed twenty medical schools that have had the highest number of medical students accepted into Urology Residency Programs. Jefferson is listed in the top twenty. Dr. Patrick Shenot, (Residency Director), Dr. Costas Lallas (Co-Director of Urology Education Programs), Dr. Leonard Frank (Co-Director of Urology Education Programs), our attendings, and our residents and fellows have made this happen and it truly represents the best of our department in our undergraduate educational programs. We expect another strong showing from the JMC class of 2012 with 12 students planning on applying to Urology programs.

TJU UROLOGY FELLOW FOR 2011-2012

Dr. Nir Kleinmann joined our department as the C.R. Bard Fellow in Endourology and Laparoscopy 2011-2012. He is also appointed as an Instructor of Urology by Jefferson Medical College and appointed to the Medical Staff of the Wilmington VA where he will staff a clinic with the residents one day a week. Dr. Kleinmann completed his medical degree from Hebrew University Medical School in Jerusalem, Israel and his urology residency from Sheba Medical Center, Tel Hashomer, Israel. He, his wife Anat and two daughters Shira and Roni look forward to living and working in the US for the next two years.
THOMAS JEFFERSON UNIVERSITY HOSPITAL ADOPTS “CYSVIEW” - NEW IMAGING AGENT TO IMPROVE DETECTION OF BLADDER CANCER

Thomas Jefferson University Hospital is one of a select number of medical centers nationwide—and currently the only one in the Delaware Valley—offering a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.

The availability of the imaging agent known as “Cysview” signals the arrival of an innovative diagnostic technology for patients who have or may have bladder cancer, and underscores Jefferson’s Kimmel Cancer Center reputation as a leading cancer care facility in the Delaware Valley.

The imaging agent is used to detect bladder cancer in individuals suspected or known to have lesion(s) in the bladder, based on a prior cystoscopy (the examination of the bladder and urethra using a cystoscope, a thin, tube-like instrument with a light and a lens for viewing). It is used with a white light setting to illuminate the bladder during a routine cystoscopy, and a blue light setting to induce and view fluorescence, thereby enabling physicians to detect lesions in the bladder.

More than 70,000 people in the United States were diagnosed with cancer of the bladder in 2009, and an estimated 14,000 Americans died from the disease last year, according to the National Cancer Institute. Bladder cancer is the fourth most common type of cancer in men, and the eighth most common in women. Smoking is the most likely cause of bladder cancer. The most common initial sign of the disease is red-colored urine, which calls for urine cytology (tests performed on cells in urine to detect disease) and cystoscopy.

“Bladder cancer can be difficult to detect. A missed diagnosis can result in delayed or incomplete treatment, which may lead to serious complications and a lower chance of survival for patients with potentially aggressive tumors,” said Leonard Gomella, M.D., F.A.C.S., the Bernard W. Godwin, Jr. Professor of Prostate Cancer, associate director for Clinical Affairs at the Kimmel Cancer Center at Jefferson, and Chair of the Department of Urology. “Cysview” represents an important advance in diagnostic technology, enabling more accurate diagnosis of bladder tumors compared to the standard technique.

“Patients with known or suspected bladder cancer can now come to Jefferson to undergo diagnostic procedures administered by physicians who have been specially trained in the use of this innovative technology.”

The standard diagnostic procedure for bladder cancer combines urine cytology and white light cystoscopy. Although cytology provides specificity and sensitivity in detecting high-grade (highly abnormal) lesions, it provides no information on the location and extent of the disease. If the cells test positive for cancer, the next step is direct visual inspection of the urothelium and mucosa (the inside of the bladder) with white light cystoscopy to localize the tumors. Physicians perform transurethral resection (TUR), a form of cystoscopy-guided biopsy, of suspicious areas of the bladder, and then test the tissue samples to determine if they are malignant.

“We are dedicated to finding new ways to improve the lives of patients living with serious diseases such as cancer, and “Cysview” is the latest example,” said Dr. Gomella. “By facilitating early diagnosis of bladder cancer, this innovative imaging agent can enable appropriate, timely treatment that may improve patients’ chances of survival.” Jefferson’s Kimmel Cancer Center participated in and has published research as one of the earliest US sites to use this agent (also called “Hexvix” internationally) with our experience extending back to 2003-2005.

This article is adapted from ABC news and the KYW news radio press releases written by TJU Medical Science Writer Steve Graff.
The 106th Annual Scientific Meeting of the American Urological Association was held at Walter E. Washington Convention Center, Washington, DC, on MAY 14-19, 2011. The Theme selected for the meeting is “Our Knowledge. Our Patients’ Lives.” Our attendees and residents had the opportunity to learn about the latest advances in urology and present their scientific endeavors. Faculty who attended are the following: Leonard Gomella, M.D., Kenneth Brownstein, M.D., Leonard Frank, M.D., Deborah Glassman, M.D., Irvin Hirsch, M.D., Scott Hubosky, M.D., Costas Lallas, M.D., Patrick Shenot, M.D. and Edouard Trabulsi, M.D. Our residents included Jim Johannes, M.D. and J.R. Zola along with our fellow – Kelly Healy, M.D.

The Annual Jefferson Urology Alumni Reception was held during the 2011 AUA meeting. Over 60 current and former faculty, residents, fellows and students stopped by to renew their connections to the Jefferson Urology family. The reception was hosted by Leonard G. Gomella, M.D. and Phillip Marone, M.D. at the Renaissance in Washington, DC. We thank Dr. Marone, Dean for Alumni Affairs and his associate Molly Gerber for making the trip to Washington on behalf of our department and Jefferson Medical College.

AUA 2011 ABSTRACTS REPRESENTING AUTHORSHIP BY TJU FACULTY & TJUH RESIDENTS

- “A Phase 2 Study - Tengion Autologous Neo-Bladder Augment™ (NBA) For Augmentation Cystoplasty In Subjects With Neurogenic Bladder Secondary To Spinal Cord Injury.” Patrick Shenot, Philadelphia, PA, T Boone, Houston, TX, D Ginsberg, Los Angeles, CA, B Green, Atlanta, GA, L Goldberg, S Sheth, M Tillinger, East Norriton, PA.
- “OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Effects on Health-Related Quality of Life.” MChancellor, Royal Oak, MI, V Patel, Irvine, CA, W Leng, Pittsburgh, PA, Patrick Shenot, Philadelphia, PA, W Lam, Irvine, CA, C Chapple, Sheffield, United Kingdom.

AUA SESSION MODERATORS BY TJU ATTENDINGS

- Michael Grasso, M.D. for Dr. Bagley. “Endoscopic Management of Upper Tract Transitional Cell Carcinoma”. Olivier Traxer (Moderator) and Demetrius Bagley (Clinical cases & discussion with audience). AUA/AFU (Association Francaise d’Urologie) sub-specialty meeting.
- Dr. Scott Hubosky – Moderator with Dr. Pramod Sagoni. Podium Session: “Urothelial Cancer: Upper Tract Tumors”.
- Dr. Leonard Gomella- Moderator with Dr. Michael Ruggieri. Poster Session: “BPH/New Technology Session”.
- Dr. Leonard Gomella-Moderator. Poster session: “Bladder Oncology & Reconstruction”.

AUA POSTGRADUATE COURSES PRESENTED BY OUR ATTENDINGS

- Course 103. “Flexible Ureteroscopy for Renal Stones”. John Honey (Director), Joel Teichman, Kenneth Pace, Michael Grasso for Demetrius Bagley (Kelly Healy-Lab).
- Course 105. “Flexible Ureteroscopy for Renal Stones”. John Honey (Director), Joel Teichman, Kenneth Pace, Michael Grasso for Demetrius Bagley (Kelly Healy-Lab).
Dr. Leonard G. Gomella was appointed Chair-Elect for the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium in Orlando, Florida. Dr. Gomella’s commitment to the advancement of prostate cancer research has been an invaluable asset to the field of prostate cancer at large and he was nominated by the Society of Urology Oncology to fill this position. The Genitourinary Cancer Symposium is attended by specialists in all disciplines of Genitourinary Oncology. Interactions with these specialists and basic science researchers and encourages collaborations in the field.

The American Society of Clinical Oncology is a nationally recognized non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology.

Dr. Gomella will serve as Program Chair for the 2012 meeting to be held in San Francisco.

In addition to serving as Program Chair, Dr. Gomella co-chaired the plenary session entitled “Emerging Trends in the Characterization and Treatment Decisions of Newly Diagnosed Prostate Cancer” as well as being one of three guest speakers for the session. His presentation was entitled “Decision Making Based on Predictors of Clinical Progression”. Other Jefferson Faculty Presentations form the Orlando, Florida February 2011 Meeting included:

- “Relationship Between the Loss of the Retinoblastoma Tumor Suppressor and Radiosensitivity.” RB Den, S Ciment, A Sharma, H Mellert, S McMahon, A Dicker, KE Knudsen, Karen Knudsen.
- “Subsequent Treatment with APC8015F and its Effect on Survival in the Control Arm of Phase III Sipuleucel-t studies”. DJ George, C Nabhan, LG Gomella, JB Whitemore, MW Frohlich.

Max Koppel, M.D., has been awarded a “Dean’s Award for Excellence in Education at Jefferson Medical College”. Dr. Mark Tykocinski presented the award to Dr. Koppel at the 2011 JMC Faculty Awards Dinner held on May 5, 2011 at the Union League of Philadelphia. This is an event where the Dean honors nominated faculty for their dedication in teaching students and by creating an exemplary role model in academic medicine.

Dr. Leonard Gomella, Dr. Mark Tykocinski, Dean of Jefferson Medical College with Dr. Max Koppel and his wife, Barbara
JEFFERSON UROLOGY AND OR STAFF SPONSOR SESSION AT NATIONAL NURSING CONGRESS IN PHILADELPHIA

Jefferson welcomed perioperative nurses to our city for the 58th Annual AORN (Association of Perioperative Registered Nurses) Congress which was held on March 19-25, 2011 at the Philadelphia Convention Center. The Congress is the largest education and networking conference of perioperative nurse professionals in the world. Over 5,000 nurses and exhibitors attended the Congress this year.

On March 23rd our Jefferson Urology and OR staff hosted a breakfast and tour for international nurses attending the Congress. The staff presented the following session entitled “Nurses & Robots & Prostates, Oh My”. Our staff who participated in this session included: Costas Lallas, M.D. (Director of Robotic Surgery for TJUH), Sonia Hurtado, RN (OR Specialty Supervisor for Urology), Darlene Bewick, MSN, RN, CRNP, Maryann Sonzogni, BSN, RN, Ann Calvaresi, BSN, BA, RN, and Theresa Getz, RN

DR. MAX KOPPEL – MEDICAL ADVISOR
INTERNATIONAL HOTELS BRIDGING HEALTHCARE CONFERENCE

Max Koppel, M.D. is serving as the Medical Advisor on the University of Delaware’s Committee regarding exploration of Medical Tourism. The co-chairs of the collaborative effort are Frederick DeMicco, Ph.D. and Ali Poorani, Ph.D. of the Department of Hotel, Restaurant, and Institutional Management at the University of Delaware.

Medical tourism (also called medical travel, health tourism or global healthcare) is a term initially coined by travel agencies and the mass media to describe the rapidly growing practice of traveling across international borders to obtain health care. Factors that have led to the increasing popularity of medical travel include the high cost of health care, long wait times for certain procedures, the ease and affordability of international travel, and improvements in both technology and standards of care in many countries. Many surgery procedures performed in medical tourism’s destinations cost a fraction of the price they do in the home country.

Medical tourism is experiencing a phenomenal growth worldwide. The hotel and hospitality industry are partners with hospitals in medical tourism. Hotels and hospitals share many common elements in this evolution. In fact, about 80 percent of hospital services are "hospitality or hotel related." To learn more about this alignment, the University of Delaware (Jefferson's academic partner since 2009) is planning a conference on Hotels Bridging Healthcare at the Grand Resort Bad Ragaz, Switzerland June 16-19, 2012. This conference is planned to provide a distinctive model on how effectively hotels and hospitals could strategically connect, share experiences and provide quality services to patients, their families and guests. A European and American focus will feature a model pioneered by the Grand Resort Bad Ragaz, Switzerland. The Conference Medical Advisor is Dr. Max Koppel of the Department of Urology.

DR. GOMELLA AT COMMONWEALTH MEDICAL COLLEGE

Dr. Gomella was invited to speak at the new “Commonwealth Medical College” in Scranton, PA on September 14, 2011. For his presentation, he discussed “The Current Controversies and Guidelines for Prostate Cancer Screening”. Dr. Jim Stefanelli (TJUH Urology Resident, 1991) and Dr. Rob Ramey (TJUH Urology Resident, 2007) are both in private practice in Scranton. They and their entire group known as Delta Medix are very involved with the growing educational program at Commonwealth Medical College. They send their regards and invite everyone to stop by and visit when they are in the Scranton area.
FACULTY COLLABORATIONS EMBARK PROSTATE CANCER THERAPEUTICS

The close collaboration among Jefferson faculty members in diverse research areas continues to lead to cutting-edge medical innovations and the Department of Urology is right in the mist of these happenings. Dr. Marja T. Nevalainen, in the Department of Cancer Biology at Jefferson’s Kimmel Cancer Center and Faculty Member of the Department of Urology, studies the role of the Stat5a/b signaling molecule in cancer development and progression. She has identified a lead compound selective inhibitor of Stat5a/b and demonstrated, in preclinical culture and animal models, that such inhibition disrupts critical Stat5a/b functions in prostate cancer cells and leads to their apoptotic death.

Dr. Nevalainen has joined forces with Dr. Vincent Njar in Jefferson’s Department of Pharmaceutical Sciences to expand on the findings with the lead compound by pursuing the design, synthesis, and testing of additional compound families. Dr. Njar is a medicinal chemist who has developed a licensed portfolio of therapeutic compounds that are currently in clinical trials. The promising research collaboration of Drs. Nevalainen and Njar has received funding through an Innovation Grant to Jefferson from the PA Department of Community and Economic Development (DCED). Further, Dr. Nevalainen is working with Drs. Leonard Gomella, Edouard Trabulsi and Costas Lallas of Jefferson’s Department of Urology and Dr. Peter McCue in the Department of Pathology, to examine the activity of the compounds in explant cultures from an extensive collection of archived human prostate cancer tissues. The multidisciplinary approach, spearheaded by the collaboration between Drs. Nevalainen and Njar, has created a braintrust and resource pool to bring the study closer to the development of a marketed product to treat prostate cancer. They are exploring further partnering and development opportunities with a number of pharmaceutical companies and regional economic development agencies, including the Science Center, BioAdvance, and Ben Franklin Technology Partners.

KAREN KNUDSEN, Ph.D. –RON ROSS AWARD

Karen Knudsen, Ph.D. was presented the prestigious Ron Ross Award. The award is in honor of Ron Ross (1949-2006), Flora L. Thornton Chairman of Preventive Medicine and the Catherine and Joseph Aresty Professor of Preventive Medicine and Urology at the Keck School of Medicine of the University of Southern California. Dr. Ross was a leading expert in hormone replacement therapy and in the causes and prevention of hormone related cancers such as prostate, breast, ovarian and endometrium.

Dr. Knudsen received this distinguish award for her research endeavors in the field of hormonal carcinogenesis, exemplifying the work of Dr. Ron Ross. Dr. Kudsen’s laboratory group focuses on critical co-factors that drive castrate resistant prostate cancer, novel therapeutic targets for treatment, and intricate mechanisms, which impinge on androgen receptor function that contribute to the lethality of the disease.

Karen Knudsen, PhD is Professor of Cancer Biology, Urology and Radiation Oncology at Kimmel Cancer Center, Thomas Jefferson University. Karen is the Director of the Greater Philadelphia Prostate Cancer Working Group, a consortium of clinicians and research scientists that collaboratively work to advance the pace and impact of prostate cancer research. Drs. Knudsen and Gomella are the Program Leaders for the Kimmel Cancer Center’s Prostate Cancer/ GU Oncology Program.

Congratulations are again in accord to Dr. Knudsen as the recipient of the Dean’s Pilot Programmatic Research Grant Initiative for 2011. This award is “to provide seed funding for the generation of critical data leading to the submission of successful NIH programmatic grants (PO1, SPORE, Training Grants, University Grants, Center Grants)."
CLINICAL TRIAL HIGHLIGHTS
Title: Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Principal Investigator: Jean Hoffman-Censits, M.D., Department of Medical Oncology
Investigator Initiated Trial, multi-institution study at Fox Chase Cancer Center and TJUH

Standard of care for clinically localized, muscle invasive (T2 – T4a) urothelial carcinoma of the bladder is cystectomy with curative intent. In the SWOG study published in The New England Journal of Medicine in 2003, in which three cycles of neoadjuvant chemotherapy followed by cystectomy was compared to cystectomy alone using a standard regimen of methotrexate, vinblastine, Adriamycin and cisplatin (standard MVAC) showed a statistically significant improvement in the rate of pathologic complete response (pT0) and overall survival in the chemotherapy arm. As a result of this landmark study and subsequent meta-analysis, consideration of neoadjuvant chemotherapy is recommended by most consensus guidelines.

Since the SWOG study was initiated, there have been significant improvements in supportive care including granulocyte stimulating factor, as well as modern prophylactic antiemetics which have improved the delivery of high dose chemotherapy. In a randomized prospective Phase III study conducted in Europe, standard dose MVAC was compared with “Dose Dense” MVAC, the same 4 drug regimen given on day 1 of treatment only with granulocyte growth factor support day 2, cycled every 14 days in the advanced setting. DD MVAC led to improved progression free survival, overall survival, response rate, and complete response rate compared with standard MVAC. DD MVAC also had improved rates of neutropenia, neutropenic fever, and mucositis compared with standard MVAC. In the neoadjuvant setting in particular, DD MVAC provides another advantage over standard MVAC, in that all three cycles can be completed within 6 weeks, thus minimizing the time to cystectomy.

Primary Endpoint:
To assess the rate of complete response (pT0) at cystectomy or ureterectomy following preoperative dose dense MVAC (DD-MVAC) in patients with muscle invasive urothelial carcinoma of the bladder or high grade upper tract urothelial carcinoma. We elect to include upper tract urothelial carcinoma in this study as an exploratory subgroup. Efficacy will be assessed separately in this group.

Secondary Endpoints:
- To assess the toxicity profile of DD-MVAC when given in the neoadjuvant setting:
- To define the number of patients who complete all three cycles of treatment without dose reduction, and to compare incidence of toxicity to the historical standard described by Grossman et al.
- To assess the 5 year overall and relapse free survival in patients who receive neoadjuvant DD-MVAC.
- To compare complete response rates between the following subgroups of study patients: Clinical N0 versus N1 among bladder patients: T2 stage without high risk features versus T2 with high risk features plus those with > T2 stage

General Inclusion Criteria
Patients must have histologically confirmed urothelial carcinoma of the bladder, ureter or renal pelvis. Bladder cancer T-stage must be T2 to T4a and muscle invasion must be established by TURBT. Upper tract tumors (ureter or renal pelvis) must be high grade urothelial carcinoma. For patients with upper tract disease, those with a voided urine cytology positive for urothelial carcinoma in the setting of cross-sectional imaging consistent with mass lesion of the renal pelvis are also eligible for study. Patients (bladder or upper tract) with clinical N0 disease or cN1 disease, are eligible for the study. Patients should have no radiographic evidence of metastatic disease. Mixed histologies which are predominantly urothelial, such as with squamous or micropapillary differentiation, are allowed so long as there is no component of small cell histology. Histology must be confirmed by a pathologist at an institution involved in this study.

- Patients must be candidates for radical cystectomy, nephroureterectomy, or segmental ureterectomy with the goal of cure.
- Age ≥18 years.
- ECOG performance status of 0 or 1
- Patients must have normal organ and marrow function, creatinine clearance >50 mg/min
- Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 2 months of study entry

To refer a patient contact: Christine Hubert, Research Coordinator at 215-955-9954.
**Jefferson Urology News Notes**

**Welcome:**
- Deanna Grossman – Coder / Biller
- Deb Day - Patient Representative
- Shari Ingram – Medical Assistant
- Monique Greco Medical Assistant
- Erica Colon – Medical Assistant
- Tracianne Czarnecki, RN – Staff Nurse
- Michelle Rodgers, RN - Lead Staff Nurse

**Congratulations!**

**2011 Service Excellence Awards**

*Haneefah Holly*
*Janelle Browning*

**Jim Johannes, MD** (TJUH Residency, 2011) has passed the Board Certification Exam. Jim is in practice in Allentown PA and reports that he is very busy.

Happy Birthday! **Dr. Stephen Strup** (TJUH Residency, 1994), Chief of the Division of Urology at the University of Kentucky, School of Medicine celebrated his 50th Birthday this year. In recognition of his special birthday, a painting entitled “Lake Reflection” by artist Jeffrey Vaughn was hung in the new University of Kentucky, Albert B. Chandler Hospital Pavilion. More in an upcoming issue of JUN.

**Congratulations!**

**Years of TJU Employment**

- **Catherine “Kit” Foster** – 25 Years/ TJU
- **Bridget Weissinger**– 10 Years/-TJUH-OR / Urology
- **Barbara Devine** – 25 Years/ Urology

**Congratulations!**

**Dr. and Mrs. Steve Don**

The Department of Urology has enjoyed our time with **Emily Feeney, Catherine “Kit” Foster and Karen Millsip** and appreciated having had the opportunity to work together. Even though we will miss them, the Department wishes them all the best towards Kit and Karen’s new career endeavors and Emily’s retirement plans.

**Farwell**

**UROLOGY FEATURED IN SEPTEMBER KING OF PRUSSIA CAMPAIGN.** The Department of Urology was promoted in the month of September at the King of Prussia Mall as well as in other venues. The Sky Banner ad promoted our prostate cancer awareness and screening programs that were held during the month of September. More on our 2011 Prostate Cancer activities in an upcoming edition of JUN.